
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is experiencing significant growing pains, causing a recent $65M guidance cut in 2026; however, with its retained data strategy from Sema4 and a potential to monetize its data, the company has promising opportunities for growth, particularly with the rare disease market, which is larger than perceived. As a market-leading rare-disease testing lab services company with a strong track record and 26 years of experience, GeneDx has a significant potential to succeed in the long run.
Bears say
GeneDx Holdings is facing significant challenges, as seen in their recent Q1 miss and lowered guidance for 2026, which was attributed to 5 different factors. Despite the potential of new markets such as pediatricians and newborn screening, conversion of early adopters in these markets may take up to 2 years according to management. Additionally, the company has a history of overpromising and underdelivering, casting doubt on their ability to accurately forecast and provide guidance. As a result, I have a negative outlook on GeneDx Holdings' stock due to these fundamental reasons.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares